Search

Your search keyword '"Agostino, R. M."' showing total 13 results
Start Over Author "Agostino, R. M."
13 results on '"Agostino, R. M."'

10. EFFECTS OF DENOSUMAB ON QUATITATIVE ULTRASOUND AND DXA MEASUREMENTS IN AROMATASE INHIBITOR-TREATED BREAST CANCER WOMEN

Author

Catalano, A., Morabito, N., Giorgio BASILE, Agostino, R. M., Gaudio, A., Bellone, F., Papalia, M., Scarcella, C., La Fauci, M. M., Ferro, C., Morini, E., Natale, G., and Lasco, A.

Subjects
aromatase, postmenopausal, breast cancer, phalangeal, ultrasound, denosumab, osteoporosis, ultrasound, phalangeal, postmenopausal, women, fractures, breast cancer, aromatase, aromatase inhibitors, denosumab, women, fractures, osteoporosis, aromatase inhibitors

12. Myositis/myasthenia after pembrolizumab in a bladder cancer patient with an autoimmunity-associated HLA: Immune–biological evaluation and case report

Author

Roberto Maisano, Giovanna Orizzonte, Giorgio Restifo, Pierpaolo Correale, Michele Caraglia, Vincenzo Dattola, Cirino Botta, Rita Agostino, Rita Emilena Saladino, Domenico Mazzacuva, Rocco Giannicola, Antonia Consuelo Falzea, Natale Daniele Calandruccio, Antonino Mafodda, Umberto Aguglia, Giovanna Bianco, Eleonora Iuliano, Vittoria Cianci, Botta, C., Agostino, R. M., Dattola, V., Cianci, V., Calandruccio, N. D., Bianco, G., Mafodda, A., Maisano, R., Iuliano, E., Orizzonte, G., Mazzacuva, D., Falzea, A. C., Saladino, R. E., Giannicola, R., Restifo, G., Aguglia, U., Caraglia, M., Correale, P., Botta C., Agostino R.M., Dattola V., Cianci V., Calandruccio N.D., Bianco G., Mafodda A., Maisano R., Iuliano E., Orizzonte G., Mazzacuva D., Falzea A.C., Saladino R.E., Giannicola R., Restifo G., Aguglia U., Caraglia M., and Correale P.

Subjects
0301 basic medicine, Oncology, Male, Case Report, Autoimmunity, Pembrolizumab, PD1-checkpoint inhibitors, medicine.disease_cause, 0302 clinical medicine, Antineoplastic Agents, Immunological, Biology (General), HLA Antigen, Myositi, PD1-checkpoint inhibitor, Spectroscopy, Myositis, General Medicine, Computer Science Applications, Myasthenia Gravi, Chemistry, Pyridostigmine, urothelial cancer, 030220 oncology & carcinogenesis, Urinary Bladder Neoplasm, Class-I/II HLA, Myasthenia, medicine.drug, Human, medicine.medical_specialty, QH301-705.5, Prognosi, Human leukocyte antigen, Antibodies, Monoclonal, Humanized, Catalysis, Inorganic Chemistry, 03 medical and health sciences, Internal medicine, medicine, Physical and Theoretical Chemistry, Adverse effect, Molecular Biology, QD1-999, Aged, business.industry, Organic Chemistry, Cancer, medicine.disease, Discontinuation, 030104 developmental biology, business
Abstract

Pembrolizumab (mAb to PD-1) has been recently approved for the therapy of pretreated urothelial cancer. Despite the efficacy, it is often accompanied by unpredictable and sometime severe immune-related (ir) adverse events (AEs). Here, we report the clinical and immune–biological characterization of a patient with a metastatic bladder cancer who developed myositis signs (M) and a myasthenia-like syndrome (MLS) during treatment with pembrolizumab. The patient presented an autoimmunity-associated HLA haplotype (HLA-A*02/HLA-B*08/HLA-C*07/HLA-DRB1*03) and experienced an increase in activated CD8 T-cells along the treatment. The symptomatology regressed after pembrolizumab discontinuation and a pyridostigmine and steroids-based therapy. This is the first report of concurrent M and MLS appearance in cancer patients receiving pembrolizumab. More efforts are needed to define early the risk and the clinical meaning of irAEs in this setting.

Published
2021

13. GOLFIG Chemo-Immunotherapy in Metastatic Colorectal Cancer Patients. A Critical Review on a Long-Lasting Follow-Up

Author

Michele Caraglia, Pierpaolo Correale, Rocco Giannicola, Nicoletta Staropoli, Cirino Botta, Pierpaolo Pastina, Antonello Nesci, Nadia Caporlingua, Edoardo Francini, Laura Ridolfi, Enrico Mini, Giandomenico Roviello, Domenico Ciliberto, Rita Maria Agostino, Alessandra Strangio, Domenico Azzarello, Valerio Nardone, Antonella Falzea, Salvatore Cappabianca, Marco Bocchetti, Graziella D'Arrigo, Giovanni Tripepi, Pierfrancesco Tassone, Raffaele Addeo, Antonio Giordano, Luigi Pirtoli, Guido Francini, Pierosandro Tagliaferri, Caraglia M., Correale P., Giannicola R., Staropoli N., Botta C., Pastina P., Nesci A., Caporlingua N., Francini E., Ridolfi L., Mini E., Roviello G., Ciliberto D., Agostino R.M., Strangio A., Azzarello D., Nardone V., Falzea A., Cappabianca S., Bocchetti M., D'Arrigo G., Tripepi G., Tassone P., Addeo R., Giordano A., Pirtoli L., Francini G., Tagliaferri P., Caraglia, M., Correale, P., Giannicola, R., Staropoli, N., Botta, C., Pastina, P., Nesci, A., Caporlingua, N., Francini, E., Ridolfi, L., Mini, E., Roviello, G., Ciliberto, D., Agostino, R. M., Strangio, A., Azzarello, D., Nardone, V., Falzea, A., Cappabianca, S., Bocchetti, M., D'Arrigo, G., Tripepi, G., Tassone, P., Addeo, R., Giordano, A., Pirtoli, L., Francini, G., and Tagliaferri, P.

Subjects
0301 basic medicine, Oncology, medicine.medical_specialty, Cancer Research, Colorectal cancer, medicine.medical_treatment, colorectal cancer, chemotherapy, lcsh:RC254-282, 03 medical and health sciences, 0302 clinical medicine, FOLFOX, Internal medicine, Medicine, Adverse effect, Original Research, Chemotherapy, business.industry, Hazard ratio, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, medicine.disease, GOLFIG, immunotherapy, metastatic, phase III clinical trial, real-world medicine, Gemcitabine, Oxaliplatin, Regimen, 030104 developmental biology, 030220 oncology & carcinogenesis, business, medicine.drug
Abstract

Background: GOLFIG is a chemo-immunotherapy regimen established in preclinical models that combines gemcitabine + FOLFOX (fluoropyrimidine backbone coupled to oxaliplatin) poly-chemotherapy with low-dose s. c. recombinant interleukin-2 (rIL-2) and granulocyte-macrophage colony stimulating factor (GM-CSF). Promising antitumor effects in metastatic colorectal cancer (mCRC) patients were obtained in previous phase II and III trials. Here we report the results of 15 years of follow-up. Methods: This is a multi-institutional retrospective analysis including 179 mCRC patients receiving GOLFIG regimen between June 2002 and June 2018. Sixty-two of them received the treatment as frontline (enrolled in the GOLFIG-2 phase III trial) and 117 as second/third line (49 enrolled in the GOLFIG-1 phase II trial and 68 as compassionate use). One hundred twelve patients showed a primary left side and 67 a primary right side; K/N-ras mutational status was available in 74 cases, and an activating mutation was detected in 33. Kaplan–Meier and Cox regression analyses were carried out to relate PFS and OS with different parameters. Results: Overall, we recorded a mean PFS and OS of 15.28 (95% CI: 10.36–20.20) and 24.6 (95% CI: 19.07–30.14) months, respectively, with 14 patients surviving free of progression for 10 years. This regimen, in our updated survey of the GOLFIG-2 trial, confirmed superiority over FOLFOX in terms of PFS (hazard ratio (HR) = 0.58, p = 0.006) with a trend to a longer OS (HR = 0.69, P = 0.06) in the first line. Our analysis also confirmed significant antitumor activity in pre-treated patients, reporting a mean PFS and OS of 12.55 (95% CI: 7.19–17.9) and 20.28 (95% CI: 14.4–26.13) months, respectively. Immune-related adverse events (irAEs) were recorded in 24% of the cases and were related to a longer survival (HR = 0.36; P = 0.0001). Finally, patients' outcome was not correlated to sex, sidedness, and MT-K/N-ras. Conclusions: The GOLFIG regimen is a reliable underestimated therapeutic option in pre-treated mCRC patients and offers a strong rationale to design further trials.

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results